Strategic Value With Achillion now part of Alexion, leverage the expanded rare disease portfolio and commercial reach to offer complementary clinical development services, regulatory affairs support, and market access strategies.

Clinical Pipeline Target the company’s focus on orally administered factor D inhibitors and rare disease programs to propose translational research collaborations, biomarkers development, and early access strategies that align with their pipeline priorities.

Financial Readiness Security of funding and mid-range revenue suggests potential for co-development or milestone-based partnerships; propose financing options, grant support, and strategic partnerships to accelerate trials and market entry.

Growth Opportunities Recent organizational changes and legacy leadership movements indicate a dynamic strategic environment; present scalable solutions for clinical operations, data management, and outsourcing to optimize efficiency during expansion.

Technology Enablement Current tech stack includes cloud, BPMN, collaboration, and database tools; offer integration-ready digital platforms for trial management, regulatory submissions, and real-world evidence collection to streamline internal workflows.